Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2961-2967

  Hirt, Déborah ^a,b,c   Ekouévi, Didier K ^c,d   Pruvost, Alain ^e   Urien, Saïk ^a,c,f   Arrivé, Elise ^c   Blanche, Stéphane ^g   Avit, Divine ^d   Amani Bosse, Clarisse ^d   Nyati, Mandisa ^h   Legote, Shini ^h   Ek, Meng L ⁱ   Say, Leakhena ^j   McIntyre, James ^h   Dabis, François ^c   Tréluyer, Jean Marc ^a,c,f  

^a Assistance Publique Hôpitaux de Paris ^*  (France)

^b CNRS   (France)

^c INSERM   (France)

^d Programme PAC CI   (Côte d’Ivoire)

^e SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ Hopital Calmette   (Cambodia)

^j INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABOR ONSET; LIQUID CHROMATOGRAPHY; NEWBORN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ANTI-HIV AGENTS; FEMALE; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 79956330149     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01377-10     Document Type: Article

References (24)

1. Anderson, P. L., T. N. Kakuda, and K. A. Lichtenstein. 2004. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38:743-753.
2. Arrive, E., et al. 2009. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 23:825-833.
3. Arrive, E., et al. 2007. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36:1009-1021.
4. Benaboud, S., et al. 2011. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1 infected women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob. Agents Chemother. 55:1315-1317.
5. Benech, H., et al. 2004. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal. Biochem. 330:172-174.
6. Blum, M. R., G. E. Chittick, J. A. Begley, and J. Zong. 2007. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J. Clin. Pharmacol. 47:751-759.
7. Capparelli, E. V., et al. 2003. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J. Clin. Pharmacol. 43:133-140.
8. Chi, B. H., et al. 2007. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:1698-1705. (Pubitemid 350100773)
9. Durand-Gasselin, L., D. Da Silva, H. Benech, A. Pruvost, and J. Grassi. 2007. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob. Agents Chemother. 51:2105-2111.
10. Durand-Gasselin, L., et al. 2008. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob. Agents Chemother. 52:2555-2563.
11. Feiterna-Sperling, C., et al. 2007. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J. Acquir. Immune Defic. Syndr. 45:43-51.
12. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
13. Gao, W. Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U. S. A. 90:8925-8928.
14. Giraud, C., et al. 2009. High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life. Clin. Pharmacol. Ther. 85:289-295.
15. Hawkins, T., et al. 2005. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39:406-411.
16. Hirt, D., et al. 2009. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin. Pharmacol. Ther. 85:182-189.
17. Kiser, J. J., et al. 2008. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 52:631-637.
18. Kuhn, E., and M. Lavielle. 2005. Maximum likelihood estimation in nonlinear mixed effects models. Comput. Stat. Data Anal. 49:1020-1038.
19. Pruvost, A., et al. 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49:1907-1914.
20. Pruvost, A., et al. 2009. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob. Agents Chemother. 53:1937-1943.
21. Pruvost, A., F. Theodoro, L. Agrofoglio, E. Negredo, and H. Benech. 2008. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells. J. Mass Spectrom. 43:224-233. (Pubitemid 351303443)
22. Ramanathan, S., G. Shen, A. Cheng, and B. P. Kearney. 2007. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J. Acquir. Immune Defic. Syndr. 45:274-279.
23. R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
24. TEmAA ANRS 12109 Study Group. 2010. Maternal and nenonatal nevirapine, tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and viral resistance. AIDS 24:2481-2488.